A newly discovered molecule (ATDR) helps repair myelin and restore nerve function in multiple sclerosis — what the yak study in Neuron (2026) actually shows
Chinese scientists studying a genetic mutation in yaks and other high-altitude animals uncovered a previously unknown myelin-repair mechanism. A gain-of-function mutation in the Retsat gene (Q247R) makes the enzyme more active in neurons, boosting production of the vitamin-A–derived signal ATDR/ATDRA, which binds RXR-γ on oligodendrocytes and drives faster remyelination. Published in Neuron, April 2026. Here is what the study really shows — and what still stands between it and a treatment for MS.
Where this news comes from
Readers ask me about this often, so I have put the practical points together in one place. In April 2026, a team from Songjiang Hospital affiliated to Shanghai Jiao Tong University School of Medicine published a paper in *Neuron* (Cell Press) titled "A gain-of-function Retsat variant from high-altitude adaptation promotes myelination via a neuronal dihydroretinoic acid-RXR-γ pathway" ([Zhang L et al., Neuron 2026](https://www.cell.com/neuron/fulltext/S0896-6273(26)00013-9)). The study went viral in health media, with headlines like "Newly discovered molecule helps repair myelin and restore nerve function in multiple sclerosis" (including the widely shared post by Partha Nandi, MD). This article separates what the study actually shows from what the headlines imply, so people living with MS can read it clearly.
Why remyelination is the "holy grail" of MS research
Every currently approved disease-modifying therapy for MS ([Ocrevus](/en/blog/ocrevus-ocrelizumab-complete-2026-guide-works-efficacy-safety-access-ms), [Kesimpta](/en/blog/kesimpta-ofatumumab-complete-2026-guide-works-efficacy-self-injection-ms), [Tysabri](/en/blog/tysabri-natalizumab-complete-2026-guide-works-affirm-efficacy-pml-risk-ms), [Mavenclad](/en/blog/mavenclad-cladribine-complete-2026-guide-short-oral-course-long-term-ms), [Tecfidera](/en/blog/tecfidera-dimethyl-fumarate-complete-2026-guide-works-define-confirm-ms), [Copaxone](/en/blog/copaxone-glatiramer-acetate-complete-2026-guide-works-gala-efficacy-ms) and others) does one thing very well: it dampens inflammation and prevents new damage to myelin. None of them repairs the myelin that has already been lost. That is why disability slowly accumulates in many patients, and why labs around the world are racing to find drugs that promote remyelination.
What the scientists actually did
The team started from a simple observation: yaks, Tibetan antelopes and other mammals living at 3,000–5,000 m altitude live in air with 40–60% less oxygen than at sea level. In humans and lowland animals, chronic low oxygen impairs myelin formation and repair. So how do these animals avoid neurological damage?
Earlier genomic work had identified a specific mutation in the *Retsat* (retinol saturase) gene — Q247R that is common in high-altitude species and rare in lowland ones. The scientists:
1. Genetically engineered mice carrying the *Retsat* Q247R mutation.
2. Raised them in low-oxygen environments simulating high altitude.
3. Compared myelin development and repair against wild-type mice.
4. Deliberately damaged myelin using demyelinating chemicals (cuprizone model) and measured how fast it recovered.
What they found
Better myelination during development
Wild-type mice in low oxygen produced less myelin and developed severe demyelination. Mice with the Q247R mutation produced normal levels of myelin even under hypoxia — the mutation appeared to protect their central nervous system.
Faster remyelination in adults
When adult mice were given cuprizone (which strips myelin), Q247R animals recovered markedly faster and more completely than controls. Alongside this, they showed more mature oligodendrocytes — the myelin-making cells.
A new signalling pathway: ATDR / ATDRA → RXR-γ
The heart of the paper is not the mutation itself but what the mutation triggers:
The Retsat enzyme helps convert vitamin A into signalling molecules. The Q247R variant makes it more active in neurons. Neurons therefore make more of a molecule called ATDR (all-trans dihydroretinoate), which the body converts into ATDRA (all-trans dihydroretinoic acid). ATDRA binds to the RXR-γ receptor on oligodendrocytes and drives them to mature — which promotes myelin repair. The key experiment: giving ATDR alone (no mutation) to wild-type mice improved remyelination after chemical demyelination.
This is what makes the paper therapeutically relevant: ATDR is a molecule the body already makes. A future drug does not have to be an entirely new synthetic — it could copy an endogenous signal, which usually means fewer surprises in toxicity.
What is the "newly discovered molecule"?
In popular headlines "the molecule that repairs myelin" refers to ATDR / ATDRA — vitamin A derivatives the brain already makes in small amounts but evidently not enough in people with MS. The idea is not to give patients vitamin A (which is toxic in high doses), but to develop specific ATDR-based drugs or analogues that could safely activate the same pathway.
What this is NOT — the honest limits
This part matters, because social media is already framing this as a "cure for MS":
- This is a mouse study, not a human study. No patient has been treated with ATDR.
- The demyelination model (cuprizone) is not autoimmune MS. It shows that myelin *can* be repaired, but not that ATDR will still work in the presence of the MS immune attack.
- There are no phase 1 clinical trials in people with MS. The road from a mouse paper to an approved drug typically takes 8–15 years and fails 90% of the time.
- Vitamin A derivatives are teratogenic (cause severe birth defects). Any future ATDR drug will have to solve that problem.
- The study does not show that ATDR reverses already-lost function — it shows faster repair of fresh lesions.
How this fits the broader 2025–2026 picture
This is not an isolated story. The last 12 months have seen several convergent discoveries suggesting remyelination is genuinely reachable, not just theoretical:
- K102 and K110 — two small molecules from UC Davis (October 2025) that regenerated myelin in mice ([ScienceDaily](https://www.sciencedaily.com/releases/2025/10/251011102259.htm)).
- D6PV (ApoC2 mimetic) — a Belgian paper (January 2026) showing enhanced remyelination via oxidative phosphorylation in oligodendrocytes ([bioRxiv 2026](https://doi.org/10.64898/2026.01.22.701034)).
- Brain sugar levels signalling myelin growth — a May 2026 study ([MSNT](https://multiplesclerosisnewstoday.com/news-posts/2026/05/04/brain-sugar-levels-act-signal-myelin-growth-study-finds/)).
- Two drug strategies from the University of Helsinki (May 2026) that boost myelin repair and cut neuroinflammation in MS models.
- Clinically, [tolebrutinib](/en/blog/latest-ms-drugs-approved-2025-2026-cenrifki-tolebrutinib-pediatric) (BTK inhibitor) became in 2025 the first drug to show an effect on non-relapsing secondary progressive MS — proving that CNS-focused therapies are feasible.
Taken together, the field is moving from "theoretically possible" to "several parallel strategies entering the clinic".
What this means for people with MS today (2026)
- There is currently no approved myelin-repair drug. Anyone offering ATDR, "vitamin-A therapy" or a "high-altitude cure" is misleading you.
- Stay on your DMT. Preventing new lesions is *exactly* what gives the brain room to repair itself. This study strengthens the case for early, effective DMT treatment.
- Follow the clinical trials. The first trials that actually measure remyelination in MS are running (opicinumab, clemastine, metformin — soon likely ATDR analogues). See [active MS trials](/en/clinical-trials).
- Lifestyle factors that support myelin still have the strongest evidence today — adequate vitamin D, no smoking, regular aerobic exercise (drives BDNF and oligodendrocyte survival), good sleep (glymphatic clearance).
What should happen next
1. Toxicology of ATDR in rodents and non-human primates (12–24 months).
2. Phase 1 safety trials in healthy volunteers — dosing, pharmacokinetics (2–3 years).
3. Phase 2a proof-of-concept in MS patients, using MRI markers of remyelination (MTR, myelin water fraction) as primary endpoints (2–3 years).
4. Phase 3 randomised placebo-controlled trials with clinical endpoints (EDSS, walk speed, visual evoked potentials) — 3–5 years.
If everything goes well (rare), the first ATDR-based MS therapy could be available around 2033–2036. That sounds far away, but for anyone diagnosed in their 20s or 30s it is a completely realistic timeframe.
The paper published in April 2026 in *Neuron* is a real scientific discovery — a previously unknown pathway (Retsat → ATDR → ATDRA → RXR-γ → oligodendrocyte maturation) that nature already uses in high-altitude animals. It is good news for the long-term outlook of MS treatment because it shows the brain can repair myelin if given the right cue. But it is not a cure, does not yet exist for humans, and does not change current treatment recommendations. The most useful things a person with MS can do in 2026 are: control inflammation with an appropriate DMT, protect the lifestyle factors that support myelin, and stay connected to an MS centre that tracks upcoming remyelination trials. The science is genuinely advancing; patience and honesty are our allies.
Sources
Zhang L et al. A gain-of-function Retsat variant from high-altitude adaptation promotes myelination via a neuronal dihydroretinoic acid-RXR-γ pathway. Neuron 2026: https://www.cell.com/neuron/fulltext/S0896-6273(26)00013-9. Cell Press news release (April 15, 2026): https://www.sciencedaily.com/releases/2026/04/260415043630.htm. Wexler M. Scientists studying yak genetics discover myelin repair mechanism. Multiple Sclerosis News Today, April 23, 2026: https://multiplesclerosisnewstoday.com/news-posts/2026/04/23/scientists-studying-yak-genetics-discover-myelin-repair-mechanism/. Mackenzie RJ. A Genetic Mutation Found in Yaks Boosts Myelin Repair. The Scientist, 2026: https://www.the-scientist.com/a-genetic-mutation-found-in-yaks-boosts-myelin-repair-74204. Science News: Yaks may hint at a way to treat brain diseases like MS: https://www.sciencenews.org/article/yaks-brain-diseases-ms-genetic-mutation. K102/K110 remyelination compounds (UC Davis, October 2025): https://www.sciencedaily.com/releases/2025/10/251011102259.htm. This article is for educational purposes only. It does not constitute medical advice and must not be used as a basis for changing treatment without consulting an MS specialist.